Advertisement
News
Advertisement

iTherX Appoints Stefan Zeuzem, M.D., as Chair of Scientific and Clinical Advisory Board

Tue, 03/15/2011 - 5:32am
Bio-Medicine.Org

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that Stefan Zeuzem, M.D., has joined the company as Chair of the Scientific and Clinical Advisory Board.  Dr. Zeuzem will lead a respected group of hepatitis thought leaders in contributing their expertise to the clinical development of iTherX's lead compound, ITX-5061, a first-in-class hepatitis C entry inhibitor.

"Stefan Zeuzem brings more than 20 years of international clinical and research leadership in hepatitis viruses, as well as liver disease and transplantation to our team. iTherX is fortunate to have Dr. Zeuzem's invaluable guidance and perspective as we advance our lead compound ITX-5061, a hepatitis C viral entry inhibitor, through clinical development," said Flossie Wong-Staal, Ph.D., Chief Scientific Officer of iTherX.  "We have established a truly dynamic and experienced scientific and clinical advisory board to bring forward this novel class of compounds.  Along with our advisors, we believe ITX-5061 has the promise of preventing the entry of the hepatitis C virus into cells while complementing existing antiviral treatment."

Dr. Zeuzem currently serves as Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany. His clinical areas of expertise include gastroenterology, hepatology, liver transplantation, endoscopy, gastrointestinal oncology, and endocrinology. Dr. Zeuzem's current research interests include cellular physiology, molecular biology of hepatitis viruses, viral kinetics, the role of hepatitis viruses in hepatocarcinogenesis, and the stratification and optimization of antiviral treatment. After receiving his medical training from the J.W. Goethe University Medical School, the University Of Cambridge School Of Clinical Medicine (United Kingdom), and the Univ

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading